Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith Kerr

Showing results (21-30 of 58) with videos related to

Pageof 6
Sort By:
Lung Cancer (Amsterdam, Netherlands)|September 14, 2020
Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapyMartin Reck, Kostas Syrigos, Skaidrius Miliauskas, et al.
Virchows Archiv : an International Journal of Pathology|July 25, 2012
EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendationsErik Thunnissen, Lukas Bubendorf, Manfred Dietel, et al.
Histopathology|May 20, 2016
PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementationIan A Cree, Richard Booton, Paul Cane, et al.
Translational Lung Cancer Research|January 20, 2025
A non-interventional biomarker study in patients with adenocarcinoma of the lung treated with nintedanib plus docetaxel following progression on chemotherapy and/or immunotherapy: LUME-BioNISMartin Reck, Konstantinos Syrigos, Skaidrius Miliauskas, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 30, 2016
ALK Immunohistochemistry in NSCLC: Discordant Staining Can Impact Patient Treatment RegimenMerdol Ibrahim, Suzanne Parry, Dawn Wilkinson, et al.
Thorax|July 5, 2011
CT screening for lung cancer in the UK: position statement by UKLS investigators following the NLST reportJohn Kirkpatrick Field, David Baldwin, Kate Brain, et al.
Thorax|January 30, 2013
Authors' responseJohn K Field, David Baldwin, Kate Brain, et al.
Virchows Archiv : an International Journal of Pathology|August 19, 2016
Testing for ROS1 in non-small cell lung cancer: a review with recommendationsLukas Bubendorf, Reinhard Büttner, Fouad Al-Dayel, et al.
Thorax|October 14, 2010
Guidelines on the radical management of patients with lung cancerEric Lim, David Baldwin, Michael Beckles, et al.
Clinical Lung Cancer|July 6, 2021
Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK TrialShirish Gadgeel, Fred R Hirsch, Keith Kerr, et al.
Pageof 6

Showing results (21-30 of 58) with videos related to

Sort By:
Pageof 6
Lung Cancer (Amsterdam, Netherlands)|September 14, 2020
Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapyMartin Reck, Kostas Syrigos, Skaidrius Miliauskas, et al.
Virchows Archiv : an International Journal of Pathology|July 25, 2012
EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendationsErik Thunnissen, Lukas Bubendorf, Manfred Dietel, et al.
Histopathology|May 20, 2016
PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementationIan A Cree, Richard Booton, Paul Cane, et al.
Translational Lung Cancer Research|January 20, 2025
A non-interventional biomarker study in patients with adenocarcinoma of the lung treated with nintedanib plus docetaxel following progression on chemotherapy and/or immunotherapy: LUME-BioNISMartin Reck, Konstantinos Syrigos, Skaidrius Miliauskas, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 30, 2016
ALK Immunohistochemistry in NSCLC: Discordant Staining Can Impact Patient Treatment RegimenMerdol Ibrahim, Suzanne Parry, Dawn Wilkinson, et al.
Thorax|July 5, 2011
CT screening for lung cancer in the UK: position statement by UKLS investigators following the NLST reportJohn Kirkpatrick Field, David Baldwin, Kate Brain, et al.
Thorax|January 30, 2013
Authors' responseJohn K Field, David Baldwin, Kate Brain, et al.
Virchows Archiv : an International Journal of Pathology|August 19, 2016
Testing for ROS1 in non-small cell lung cancer: a review with recommendationsLukas Bubendorf, Reinhard Büttner, Fouad Al-Dayel, et al.
Thorax|October 14, 2010
Guidelines on the radical management of patients with lung cancerEric Lim, David Baldwin, Michael Beckles, et al.
Clinical Lung Cancer|July 6, 2021
Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK TrialShirish Gadgeel, Fred R Hirsch, Keith Kerr, et al.
Pageof 6